t be his night off." no magic bullets for most of the problems term 'placebo, which does nobody any that ail us today," Jonas said. "Diabetes, good," Robert Temple told me, echoing immune-system disorders, chronic pain, a complaint made by virtually every- cancer. Our illnesses are complex, and we one who deals

alse, misleading or lacking fair balance" if it stated or implied that "Risperdal is superior to haloperidol [Haldol]." The letter was signed by Dr. Robert Temple, a highly regarded specialist in clinical trials who had joined the FDA in 1972. "Our role is not to decide that one drug is more effective than an

faction of the F.D.A. "One of the absolutely fundamental problems that we have is the use of the • term 'placebo,' which does nobody any good," Robert Temple told me, echoing a complaint made by virtually every- one who deals with the subject. Temple, who has for many years run the F.D.A.'s drug-evaluat